Klymchenko team, in collaboration with BrightSens Diagnostics and teams of Pfeiffer (UPR9002-CNRS ARN) and Fafi- Kremer (HUS), has developed a revolutionary technology for ultra-sensitive detection of RNA and DNA, with applications in cancer diagnostics and viral diseases such as SARS-CoV-2. By integrating ultra-bright polymer nanoparticles, equivalent to 10,000 rhodamine molecules, in a sandwich hybridization assay with magnetic beads, this method achieves one of the lowest detection limits reported for this type of optical assay (0.3 femtomolar).
A major advantage of this approach is that it enables direct detection of viral RNA in clinical samples, without the need for enzymatic amplification and complex nucleic acid extraction. This technological advance offers promising prospects for accelerating the molecular diagnosis of diseases and facilitating high-throughput testing in medical laboratories.
Congratulations to the first author, Elisabete Silva from BrightSens Diagnostics, the former member of Klymchenko Team and all co-authors.
Direct Zeptomole Detection of RNA Biomarkers by Ultrabright Fluorescent Nanoparticles on Magnetic Beads Elisabete Cruz DaSilva, Paraskevi Gaki, Fabien Flieg, Melanie Messmer, Floriane Gucciardi, Yevheniia Markovska, Andreas Reisch, Samira Fafi-Kremer, Sébastien Pfeffer, Andrey S. Klymchenko
